20 articles
A newly identified enzyme links lactate metabolism to liver cancer progression, and a natural compound delivered via nanoparticles shows striking anti-tumor results.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
Cambridge scientists engineer a nanoprobe that detects therapy-induced senescence non-invasively through a simple urine colorimetric test.
A pyruvate metabolism enzyme suppresses leucine catabolism to keep mTOR active in liver cancer — and blocking it shrinks tumors in vivo.
New non-invasive urine protein test accurately predicts which biliary tract cancer patients will respond to immunotherapy treatment.
A Cochrane meta-analysis of 17 RCTs finds blue light TURBT reduces bladder cancer recurrence and progression, especially in intermediate- and high-risk patients.
Scientists explore how exosomes in urine samples could revolutionize early cancer detection through simple, non-invasive testing.
Early PSMA upregulation after enzalutamide predicts shorter survival, but adding Lu-177-PSMA-617 improves outcomes in resistant prostate cancer.
High-level randomized evidence quantifies genitourinary toxicity burden over time following prostate radiotherapy, with direct implications for treatment decisions.
Researchers uncover how cancer cells evade ADC therapy by suppressing drug uptake — and identify a drug target to reverse resistance.
A next-gen RAS inhibitor called daraxonrasib targets KRAS-mutant cholangiocarcinoma, showing strong preclinical results and early clinical activity.
Ginsenoside Rh4 suppresses colorectal cancer by boosting Akkermansia muciniphila and elevating protective bile acid UDCA via FXR signaling.
A macrophage-derived metabolite rewires tumor metabolism and flips immune cells from tumor-promoting to tumor-fighting.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
New research reveals how bone marrow cells produce taurine that feeds leukemia stem cells, offering potential therapeutic targets.
A tryptophan-derived gut metabolite suppresses colorectal cancer by blocking a key glycolysis enzyme via STAT3 inhibition.
A newly discovered hepatic micropeptide suppresses liver cancer progression by jamming a key mitochondrial RNA processing complex.
Scientists discover how two microbes team up to accelerate colon cancer, but L-arginine may disrupt their deadly partnership.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
